WHO Designates Resomelagon as Key Dengue Drug Candidate

The World Health Organization (WHO) has identified SynAct Pharma's resomelagon as a promising dengue therapeutic candidate. Published in Lancet Microbe, this once-daily oral pro-resolution therapy is one of six drugs with sufficient efficacy data to warrant advanced clinical development. This WHO validation underscores resomelagon's potential to address dengue globally, moving it closer to becoming a viable treatment option.